Disease progression in Patients with Parkinson’s disease uncontrolled on oral medication – a prospective, multicenter, observational study to assess health related quality of life over 24 months in Germany - PLUTO

euroTransData GmbH0 个研究点目标入组 258 人开始时间: 2023年6月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•male, female, or non-binary
•Patients with confirmed idiopathic Parkinson’s disease
•Using oral levodopa treatment
•Patients with Parkinson’s disease in MANAGE PD categories 2 and 3
•Willingness to sign and date a Patient Authorization Form to use and disclose personal health information (or informed consent form if required)
•Being able to speak and understand the language of the provided patient questionnaire

•Participation in a concurrent clinical study
•Patients with Parkinson’s disease in MANAGE PD category 1
•Significant uncertainty around the diagnosis of PD (i.e. symptoms present such as early falls or early autonomic disturbances or lack of levodopa responsiveness)
•Current or past treatment with a device aided therapy (eg, LCIG, LECIG, CSAI, DBS) at baseline.

发起方

euroTransData GmbH